Liping Dou
Clinical trials sponsored by Liping Dou, explained in plain language.
-
Double-Targeted immune cells aim to stop leukemia return
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, modified to attack two targets (CD22 and CD19) on leukemia cells. It is for people with standard-risk B-cell acute lymphoblastic leukemia who are already in remission. The goal is to see if this therapy is safe …
Phase: PHASE1, PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated May 26, 2026 08:29 UTC
-
New CAR-T therapy aims to keep High-Risk leukemia in remission
Disease control Recruiting nowThis study is testing a new treatment using specially engineered immune cells (CAR-T cells) that target two markers on leukemia cells (CD22 and CD19). The goal is to prevent the cancer from coming back in people with high-risk B-cell acute lymphoblastic leukemia who have already …
Phase: PHASE1, PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
Engineered immune cells aim to stop lymphoma in its tracks
Disease control Recruiting nowThis study tests a new approach using a patient's own immune cells, modified to target two markers (CD19 and CD22) on lymphoma cells, as a first-line consolidation treatment. It is for people with follicular lymphoma who had only a partial response to initial chemotherapy. The go…
Phase: PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated May 20, 2026 11:56 UTC